MULTIPLE ENDOCRINE NEOPLASIA: A COMPREHENSIVE OVERVIEW

Multiple Endocrine Neoplasia (MEN) syndromes are rare hereditary disorders involving tumor development across multiple endocrine glands. Advances in genetics and molecular endocrinology have transformed diagnosis, prevention, and treatment.

HISTORY

Familial clustering of endocrine tumors has been recognized since the early 20th century. The concept of Multiple Endocrine Neoplasia emerged in the 1950s when clinicians linked these disorders to specific genetic and glandular patterns1.

Back to top ↑

TYPES AND SUBTYPES

MEN Type 1 (MEN1)

Primarily affects the parathyroid glands, pancreas, and pituitary. Common features include hypercalcemia from parathyroid adenomas, pituitary prolactinomas, and pancreatic neuroendocrine tumors.

MEN Type 2 (MEN2)

  • MEN2A: Medullary thyroid carcinoma, pheochromocytoma, and parathyroid adenoma.
  • MEN2B: Medullary thyroid carcinoma, pheochromocytoma, mucosal neuromas, and a Marfanoid habitus.
Key Point: MEN2 is driven by mutations in the RET proto-oncogene, requiring genetic screening of family members.
Back to top ↑

PHYSICAL EXAMINATION AND PRESENTATION

  • MEN1: Hypercalcemia, pituitary tumors, and pancreatic endocrine tumors.
  • MEN2A: Neck mass from medullary thyroid carcinoma, episodic hypertension, and hypercalcemia.
  • MEN2B: Neuromas on lips/tongue, skeletal changes resembling Marfan syndrome, and endocrine symptoms.
Back to top ↑

WORKUP AND DIAGNOSTIC TESTING

Biochemical Tests

  • Serum calcium and parathyroid hormone (PTH) for parathyroid evaluation.
  • Prolactin and pituitary hormones for pituitary involvement.
  • Urinary metanephrines for pheochromocytoma detection2.

Imaging

MRI or CT scans identify lesions in endocrine glands and guide surgical planning.

Genetic Testing

MEN1 gene mutations confirm MEN1 diagnosis, while RET gene mutations indicate MEN2 syndromes3.

Key Point: Genetic counseling is essential for at-risk family members, guiding early intervention and prevention.
Back to top ↑

TREATMENT STRATEGIES

  • MEN1: Surgical resection for symptomatic parathyroid, pituitary, or pancreatic tumors; ongoing surveillance for recurrence.
  • MEN2A and MEN2B: Prophylactic thyroidectomy for RET mutation carriers, adrenalectomy for pheochromocytoma, and vigilant lifelong follow-up.
Back to top ↑

PATIENT STORIES

Jane’s Diagnosis

Jane, 29, presented with fatigue and hypercalcemia, later found to have parathyroid and pancreatic tumors. Genetic testing confirmed MEN1, emphasizing the importance of investigating multiple endocrine abnormalities.

Alex’s Early Alert

A 13-year-old boy with bumpy lips and a tall, slender frame was diagnosed with MEN2B after genetic testing confirmed a RET mutation. Early thyroidectomy prevented aggressive medullary thyroid carcinoma.

Back to top ↑

CONCLUSION

Multiple Endocrine Neoplasia syndromes, while rare, carry profound implications for patients and their families. Advances in molecular genetics allow earlier detection, risk stratification, and targeted management—transforming prognosis and quality of life.

Back to top ↑

REFERENCES

  1. Marx S, et al. Multiple Endocrine Neoplasia Type 1: Clinical and Genetic Topics. Ann Intern Med. 2005;143(5):326-338.
  2. Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942.
  3. Eng C. Genetics of Multiple Endocrine Neoplasia Type 2A, 2B, and Familial Medullary Thyroid Carcinoma. Annu Rev Med. 1996;47(1):365-374.

Note: This educational article is not a substitute for medical advice. Consult current clinical guidelines and genetic counseling protocols.

Back to top ↑
Dr. Michael Baruch
mibaruch@gmail.com • +1 (201) 803-2112
© Dr. Michael Baruch • Educational content – not medical advice.